{"pub": "independent", "url": "https://independent.co.uk/news/health/zantac-cancer-ranitidine-sales-suspended-cvs-health-fears-a9126126.html", "downloaded_at": "2019-09-30 11:31:26.834619+00:00", "title": "Zantac sales suspended by retailer over cancer fears", "language": "en", "text": "A US retailer has said it will suspend sales of popular heartburn treatment Zantac at its pharmacies over a fears it could be linked to an increased risk of cancer.\n\nCVS Health Corp said it will also discontinue its own-brand ranitidine products, which help reduce stomach acid, until further notice.\n\nThe US Food and Drug Administration (FDA) found traces of a known carcinogen in some medicines containing the drug ranitidine, including Zantac products, in findings published earlier this month.\n\nWe\u2019ll tell you what\u2019s true. You can form your own view. From 15p \u20ac0.18 $0.18 USD 0.27 a day, more exclusives, analysis and extras.\n\nWalgreens and Walmart have also stopped selling Zantac.\n\n\u201cThis action is being taken out of an abundance of caution due to a recent Product Alert from the FDA,\u201d a CVS Health statement said, \u201cthat ranitidine products may contain a low level of nitrosodimethylamine (NDMA), which is a probable human carcinogen.\u201d\n\nShape Created with Sketch. New smoking graphics proposed by the FDA Show all 12 left Created with Sketch. right Created with Sketch. Shape Created with Sketch. New smoking graphics proposed by the FDA 1/12 Reuters 2/12 Reuters 3/12 Reuters 4/12 Reuters 5/12 Reuters 6/12 Reuters 7/12 Reuters 8/12 Reuters 9/12 Reuters 10/12 Reuters 11/12 Reuters 12/12 Reuters 1/12 Reuters 2/12 Reuters 3/12 Reuters 4/12 Reuters 5/12 Reuters 6/12 Reuters 7/12 Reuters 8/12 Reuters 9/12 Reuters 10/12 Reuters 11/12 Reuters 12/12 Reuters\n\nThe FDA is continuing investigations into whether low levels of NDMA in the medicines could be dangerous for patients.\n\n\u201cThe levels that FDA is finding in ranitidine from preliminary tests barely exceed amounts found in common foods,\u201d CVS Health Corp said.\n\nDespite being taken of pharmacy shelves until further notice, Zantac and CVS brand ranitidine products have not been recalled by the retailer.\n\nThe FDA said it does not currently advise patients to stop taking ranitidine medicines.\n\nIf patients wish to change their ranitidine medication, however, the FDA said other drugs used for similar treatments could be available to them and suggested speaking to a healthcare professional.\n\nRanitidine is used to treat indigestion and heartburn by reducing the amount of acid your stomach makes.\n\nThe drug can also be taken for stomach ulcers.\n\nIndependent news email Only the best news in your inbox Independent news email Only the best news in your inbox Enter your email address Continue Continue Please enter an email address Email address is invalid Fill out this field Email address is invalid Email already exists. Log in to update your newsletter preferences Register with your social account or click here to log in I would like to receive morning headlines Monday - Friday plus breaking news alerts by email Update newsletter preferences\n\nAll types of ranitidine are available on prescription in the UK, with the lowest strength tablets available for purchase, according to the NHS website.\n\nNovartis AG\u2019s Sandoz unit said last week it was halting distribution of Zantac in all its markets, including the US and Canada, following safety review of the drug by US and European drug regulators.", "description": "A US retailer has said it will suspend sales of popular heartburn treatment Zantac at its pharmacies\u00a0over a fears it could be linked to an increased\u00a0risk\u00a0of\u00a0cancer. CVS Health Corp said it\u00a0will also discontinue its own-brand ranitidine\u00a0products, which help reduce stomach acid,\u00a0until further notice.", "authors": ["Zoe Tidman"], "top_image": "https://static.independent.co.uk/s3fs-public/thumbnails/image/2019/09/30/10/zantac-cancer-fears-cvs.jpg", "published_at": "2019-09-30"}